Skip to content
☰ Menu
Open access · US-GOV via ClinicalTrials.gov Clinical trial

An Open-label, Multicenter Safety and Tolerability Study of VTS-270 (2-hydroxypropyl-β-cyclodextrin) in Pediatric Subjects Aged < 4 Years With Neurologic Manifestations of Niemann-Pick Type C (NPC) Disease

Authors not listed

Vtesse, LLC, a Mallinckrodt Pharmaceuticals Company · 2020

Dysbiosis Human Randomized controlled trial
＋ Sign in to save

Abstract

This is a Phase-2, multicenter, multiple dose, open-label, 2-part evaluation study which will primarily assess the safety and tolerability of VTS-270 (2-hydroxypropyl beta-cyclodextrin \[HP-β-CD\]) in pediatric participants with age \<4 years.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
ClinicalTrials.gov
Canonical
link ↗
Fetched
2026-10-13 MST

Cite this

APA
Anonymous. (2020). An Open-label, Multicenter Safety and Tolerability Study of VTS-270 (2-hydroxypropyl-β-cyclodextrin) in Pediatric Subjects Aged < 4 Years With Neurologic Manifestations of Niemann-Pick Type C (NPC) Disease. <em>Vtesse, LLC, a Mallinckrodt Pharmaceuticals Company</em>. https://clinicaltrials.gov/study/NCT03687476
Vancouver
Anonymous. An Open-label, Multicenter Safety and Tolerability Study of VTS-270 (2-hydroxypropyl-β-cyclodextrin) in Pediatric Subjects Aged < 4 Years With Neurologic Manifestations of Niemann-Pick Type C (NPC) Disease. Vtesse, LLC, a Mallinckrodt Pharmaceuticals Company. 2020.
BibTeX
@misc{anon2020AnOpen, title = {An Open-label, Multicenter Safety and Tolerability Study of VTS-270 (2-hydroxypropyl-β-cyclodextrin) in Pediatric Subjects Aged < 4 Years With Neurologic Manifestations of Niemann-Pick Type C (NPC) Disease}, author = {Anonymous}, journal = {Vtesse, LLC, a Mallinckrodt Pharmaceuticals Company}, year = {2020}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings